022 24172311
Sections
Search
DealCurry
Equity
Venture Capital
Private Equity
M&A

Banner
DataBoard Demo
Mergers & Acquisitions | 16 April 2012

Piramal Healthcare Acquires Bayer AG's Molecular Imaging Portfolio

by Irfan Khan
Piramal Healthcare Acquires Bayer AG's Molecular Imaging Portfolio
Share on Social Media Email Facebook Twitter Linkedin
 
@irfan
Piramal Healthcare has acquired the molecular imaging development portfolio of Bayer Pharma AG. The terms of the deal were not disclosed, however the deal involves certain milestone and royalty payments.

The acquisition is being made through it's newly created subsidiary - Piramal Imaging SA. The portfolio includes rights to florbetaben, that helps detect beta-Amyloid plaque deposition in the brain – an indication of probable Alzheimer’s disease.

Florbetaben is a radioactive compound being developed by Bayer as an imaging agent for the detection of beta-Amyloid plaque deposition in the brain, which is the pathological hallmark of disease in probable Alzheimer’s disease patients.

IFC May Invest $5Mn In Infuse Capital

IFC May Invest $5Mn In Infuse Capital

IFC may invest upto $5Mn in Infuse Capital - an incubation and early stage fund aimed at seeding and supporting scalable ventures in India through equity investment up to US $1.5Mn per venture.

Read More...

CapitaLand Commercial to acquire majority stake in Singapore office tower for about $285m

CapitaLand Commercial to acquire majority stake in Singapore office tower for about $285m

Singapore’s sizeable office real estate finance trust by value, the CapitaLand Commercial Trust Management Limited, is all set to buy remaining 60 percent stake in CapitaGreen - Office Space, for about S$393 million ($285 million) from its partners CapitaLand Ltd. and Mitsubishi Estate Asia Pte

Read More...
Subscribe
Enter your Email address
to receive all the news